NORWALK, CT
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC, founded in 1998, is a mid-sized nonprofit in the Diseases & Disorders sector that reported $29.1M in total revenue in fiscal year 2024. Revenue decreased 14% compared to the prior year. Expenses of $35.6M exceeded revenue, resulting in a 22% operating deficit.
THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING ACUREFOR MULTIPLE MYELOMA PATIENT. WE DRIVE THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGE DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES AND EMPOWER MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO OUR MISSION IS OUR COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES WE PURSUE. SINCE OUR INCEPTION, THE MMRF HAS COMMITTED OVER $500 MILLION FOR RESEARCH, OPENED NEARLY 100 CLINICAL TRIALS, AND HELPED BRING 15+ FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS.
THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND...
THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES.IN 2024, THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC, BEGINNING IN PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA TO OPTIMIZE THE USE OF CURRENTLY AVAILABLE AND NEW TREATMENTS, WITH THE GOAL OF MAXIMIZING EFFICACY WHILE MINIMIZING SIDE EFFECTS. IN NOVEMBER, THE FIRST PATIENT WAS ENROLLED IN THE FIRST ARM OF THE HORIZON CLINICAL TRIALS PROGRAM, HORIZON ONE, WHICH WILL ASSESS DOSING APPROACHES WITH TECVAYLI (TECLISTAMAB). THIS FIRST ARM IS DESIGNED TO DETERMINE WHETHER THIS TREATMENT CAN BE GIVEN LESS FREQUENTLY OR EVEN STOPPED ENTIRELY. THE HORIZON CLINICAL TRIALS PROGRAM USES AN ADAPTIVE PLATFORM DESIGN, WHICH MAKES IT POSSIBLE TO TEST MULTIPLE THERAPIES AT THE SAME TIME, TO DETERMINE THE BEST COMBINATION, SEQUENCE, AND DURATION OF TREATMENT TO IMPROVE PATIENT OUTCOMES. WITH THIS DESIGN AND MULTI-INSTITUTIONAL COOPERATION, HORIZON IS UNIQUELY POSITIONED TO ADDRESS RESEARCH QUESTIONS THAT OTHER TYPES OF TRIALS ARE NOT EQUIPPED TO INVESTIGATE.
THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO...
THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MULTIPLE MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MULTIPLE MYELOMA. IN 2024 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS.
THE IMMUNE ATLAS PROGRAM IS A COLLABORATION BETWEEN THE MMRF AND FIVE LEADING ACADEMIC MEDICAL CENTERS. THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE...
THE IMMUNE ATLAS PROGRAM IS A COLLABORATION BETWEEN THE MMRF AND FIVE LEADING ACADEMIC MEDICAL CENTERS. THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE FOR MYELOMA PATIENTS. THE ATLAS DESCRIBES THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASE AND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH GUIDELINES AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM. IN SEPTEMBER 2024, THE MMRF PRESENTED DATA FROM THE ATLAS AT THE 21ST INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING IN RIO DE JANEIRO, BRAZIL, WHICH REINFORCED THE VALUE OF THE MMRF'S INTEGRATED CLINICAL AND TRANSLATIONAL CAPABILITIES
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $29,101,414 | $33,950,590 | -0.1% |
| Expenses | $35,604,337 | $41,890,829 | -0.2% |
| Net Income | $-6,502,923 | $-7,940,239 | -0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| KATHY GIUSTI | FOUNDER & DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| THOMAS CONHEENEY | CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| GERALD MCDOUGALL | VICE CHAIRMAN | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| KENNETH ANDERSON MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KAREN ANDREWS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RODNEY GILMORE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID LUCCHINO | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| LORI TAUBER-MARCUS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| HUGH MARTIN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SUSAN MARVIN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| WILLIAM MCKIERNAN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL MORTIMER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID PARKINSON MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MARIE PINIZZOTTO MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| ADRIAN ROSENKRANZ | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| STEVE SHAK MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KIMBERLY WHITE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL ANDREINI | PRESIDENT & CEO | 40.00 |
Officer
|
$466,042 | $26,280 | $492,322 |
| ROBERT MIANI | TREASURER & CFO, THRU JUNE 2024 | 40.00 |
Officer
|
$328,624 | $13,291 | $341,915 |
| KAREN DIETZ | SECRETARY, CAO & GENERAL COUNSEL | 40.00 |
Officer
|
$259,764 | $37,953 | $297,717 |
| ALAN HEITNER | TREASURER & CFO, AS OF OCT. 2024 | 40.00 |
Officer
|
$46,379 | $1,852 | $48,231 |
| ANNE QUINN YOUNG | CHIEF MISSION OFFICER | 40.00 |
Key Emp
|
$335,322 | $18,535 | $353,857 |
| GEORGE MULLIGAN | CHIEF SCIENTIFIC OFFICER | 40.00 |
Key Emp
|
$342,276 | $45,540 | $387,816 |
| CHRISTOPHER WILLIAMS | VP OF ALLIANCE MANAGEMENT | 40.00 |
Key Emp
|
$218,145 | $36,828 | $254,973 |
| HEARN CHO | CHIEF MEDICAL OFFICER | 32.00 |
Key Emp
|
$204,200 | $8,168 | $212,368 |
| STEPHANIE OESTREICH | MANAGING DIRECTOR, MIF | 40.00 |
Key Emp
|
$337,767 | $26,864 | $364,631 |
| KATIE WOZNIAK | VP OF CLINICAL RESEARCH | 40.00 |
Key Emp
|
$218,889 | $37,919 | $256,808 |
| GREG RUBENSTEIN | VP OF MARKETING | 40.00 |
Highest
|
$210,723 | $39,864 | $250,587 |
| JOANNE PUGLIA | SR DIRECTOR FINANCE, CONTROLLER | 40.00 |
Highest
|
$197,545 | $9,187 | $206,732 |
| MARK HAMILTON | ASSOCIATE DIRECTOR, RESEARCH | 40.00 |
Highest
|
$244,473 | $12,496 | $256,969 |
| BRIAN HOCHBERG | PRINCIPAL GIFT OFFICER | 40.00 |
Highest
|
$177,081 | $35,811 | $212,892 |
| HEATHER STEIGER | SR DIRECTOR DIGITAL MARKETING | 40.00 |
Highest
|
$175,571 | $24,207 | $199,778 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $29,101,414 | $35,604,337 | $66,397,148 | $-6,502,923 |
| 2023 | $33,950,590 | $41,890,829 | $80,227,632 | $-7,940,239 |
| 2022 | $45,044,474 | $38,280,730 | $89,097,661 | $6,763,744 |
| 2021 | $42,311,196 | $37,647,063 | $85,401,847 | $4,664,133 |
| 2020 | $26,787,219 | $28,545,732 | $73,276,923 | $-1,758,513 |
| 2019 | $43,968,062 | $33,588,092 | $79,154,355 | $10,379,970 |
| 2018 | $44,172,260 | $36,242,359 | $69,711,900 | $7,929,901 |
Compare THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC with other nonprofits in Connecticut and across the country.